INSM
INSMED IncPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 13 to May 22 ▼ 4 days of insider sells: $5.1M by 3 insiders, avg $109.75
- Jun 3 to Jun 8 ▼ 3 days of insider sells: $2.6M by 5 insiders, avg $100.27
- Jun 10 ▼ Josh Gottheimer sold $1,001 - $15,000, last disclosed Jul 8
- Jun 22 Trial readout: Results Pending: Treprostinil Palmitil Inhalation Powder (…
- Jun 22 to Jun 25 ▼ 2 days of insider sells: $2.4M by 2 insiders, avg $102.73
- Jun 30 ▲ 11 funds open new positions (13F)
- Jul 6 to Jul 9 ▼ 2 days of insider sells: $2.6M by 2 insiders, avg $113.43
- Aug 6 to Aug 17 ▼ 3 days of insider sells: $36.1M by 3 insiders, avg $132.70
- Aug 6 ▲ Insmed reported Q2 2026 revenue of $425.5M, crushing consensus estim…
- Sep 9 ▼ 1 insider sell $3.1M at $124.00
- Sep 30 ▼ Short interest jumps 27.8% to 13.80M
- Oct 12 ▼ Wolfe Research downgrades
Signal stack
Where each data set points today.
- InsidersBEARISH
7 insiders sold $53.0M.
- InstitutionsMIXED
Q2 2026: 74 added (11 new), 60 trimmed or exited. Largest new: Maverick Capital $229.3M, Hrt Financial $73.6M.
- AnalystsBULLISH
29 of 31 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +4.5% to 14.08M shares. 3.6 days to cover, ≈6.4% of shares.
- TrendUPTREND
11% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | TRIM | $1.1B |
| Capital International Investors | ADD | $878.3M |
| AMERIPRISE FINANCIAL INC | DOUBLED | $658.9M |
| Orbis Allan Gray Ltd | DOUBLED | $647.9M |
| UBS Group AG | ADD | $275.6M |
| MAVERICK CAPITAL LTD | NEW | $229.3M |
| MILLENNIUM MANAGEMENT LLC | ADD | $218.4M |
| Qube Research & Technologies Ltd | DOUBLED | $179.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
31 analystsPrice is below the lowest target. Median implies +59%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 2, 2026 | Guggenheim MAINTAIN | Buy |
| Oct 21, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Oct 12, 2026 | Wolfe Research DOWNGRADE | Peer Perform |
| Oct 12, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 30, 2026 | Barclays MAINTAIN | Overweight |
| Sep 15, 2026 | Roth Capital REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Hudson Paul Director Oct 19, 2026 | AWARD | 6,139 sh |
Koppikar Utpal Director Oct 19, 2026 | AWARD | 6,139 sh |
Brennan David R Director Sep 9, 2026 | SELL | $3.1M |
SHAROKY MELVIN MD Director Aug 17, 2026 | SELL | $637.6K |
Adsett Roger Chief Operating Officer Aug 10, 2026 | EXERCISE | $1.3M |
Adsett Roger Chief Operating Officer Aug 10, 2026 | EXERCISE | $2.5M |
Adsett Roger Chief Operating Officer Aug 10, 2026 | SELL | $32.0M |
Adsett Roger Chief Operating Officer Aug 10, 2026 | EXERCISE | $1.1M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
24 filings · 6 bullish · 3 bearish · 15 neutral- NEUTRAL 144Nov 3, 2026
Sara Bonstein, a former officer of Insmed, filed a Form 144 notice of intent to sell 10,261 shares…
This is a routine tax-withholding sale by a former officer, not a discretionary insider sale. No material impact on the stock is expected. Monitor for any subsequent Form 4 filings to confirm the…
- NEUTRAL 3Nov 3, 2026
Patrick Kane filed a Form 3 initial statement of beneficial ownership upon becoming Corporate…
Monitor future Form 4 filings by Patrick Kane for any open-market purchases or sales, which would provide insight into insider sentiment. No immediate trading signal from this initial filing.
- BULLISH 8-KOct 29, 2026
Insmed reported Q3 2026 total revenue of $524.4M, beating the $499.5M consensus, driven by…
The strong BRINSUPRI launch trajectory and raised guidance signal accelerating commercial execution. Key catalysts ahead: ARIKAYCE PDUFA decision on January 28, 2027 for label expansion, and Japan…
- BULLISH INST-CLUSTEROct 20, 2026
A bullish institutional cluster emerged in INSM during Q3 2026, with 5 asset managers adding or…
The concentrated buying by Assenagon (a systematic/quantitative manager) and smaller asset managers suggests a shared thesis around Insmed's ARIKAYCE revenue trajectory or upcoming pipeline…
All INSM filing & press-release reports (24)
- 144 reportNov 3, 2026
- 3 reportNov 3, 2026
- 8-K reportOct 29, 2026
- INST-CLUSTER reportOct 20, 2026
- 8-K reportOct 20, 2026
- 8-K reportOct 5, 2026
- CLUSTER reportAug 19, 2026
- CLUSTER reportAug 12, 2026
- 8-K reportAug 6, 2026
- INST-CLUSTER reportJul 24, 2026
- BMO Capital initiates INSM at Outperform, PT $192 (+78.6%)Jul 21, 2026
- 8-K reportJul 16, 2026
- CLUSTER reportJun 26, 2026
- CLUSTER reportJun 5, 2026
- CLUSTER reportJun 5, 2026
- S-3ASR reportMay 15, 2026
- CLUSTER reportMay 15, 2026
- 144 reportMay 13, 2026
- CLUSTER reportMay 4, 2026
- 8-K reportMay 7, 2026
- CLUSTER reportMar 30, 2026
- 8-K reportApr 7, 2026
- CLUSTER reportMar 30, 2026
- DEFA14A reportApr 1, 2026